Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
Date:10/14/2008
its drug development activities in infectious diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com. ViroPharma routinely posts information that may be important to investors in the Investor Relations and Media sections of our web site, including press releases. We encourage investors to consult these sections of our web site regularly for important information about ViroPharma.
'/>"/>
| SOURCE ViroPharma Incorporated Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. ViroPharma to Present at Three October Healthcare Conferences
2. ViroPharma to Present at Three September Healthcare Conferences
3. ViroPharma To Acquire Lev Pharmaceuticals
4. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
5. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
6. ViroPharma to Present at Two Upcoming Healthcare Conferences
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
9. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
10. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
11. ViroPharma to Present at the BIO CEO & Investor Conference
Post Your Comments:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations , Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3[0] Navigating the Dynamic Indian Clinical Trial Landscape, New Webinar Hosted by Xtalks[0] Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032[0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology[0] Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval
... -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: ... and pharmaceutical raw materials,for use in pharmaceutical, nutraceutical ... financial results second quarter 2008 which,ended June 30 ... markets close., Huifeng,s earnings release and related ...
... 4 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarterly royalty payment of approximately $2.1 million ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease. ... quarterly royalty payments on certain,sales of Memantine ...
... announced partnership, Grid Dynamics and GridGain teamed up to develop the ... ... San Francisco, CA (PRWEB) August 4, 2008 -- Following ... up to develop the largest publicly known grid scalability test for ...
Cached Biology Technology:Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 2Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 3Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of MemantineGrid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2... The University of Miami,s Rosenstiel School of Marine and ... E.M. Rickaby, Ph.D., as recipient of the 2009 Rosenstiel ... Fellow of Wolfson College, Rickaby works in the Department ... current research on the interaction between marine phytoplankton and ...
... of years, green plants have employed photosynthesis to capture ... A goal of scientists has been to develop an ... produce liquid fuels from carbon dioxide and water. Researchers ... Laboratory (Berkeley Lab) have now taken a critical step ...
... the sea, and are responsible for providing nearly half of ... However, unlike their counterparts on land, the marine plants ... human sight. Consequently, we are still in a very ... phytoplankton biology and ecology. In a new paper published ...
Cached Biology News:Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 2Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 3Turning sunlight into liquid fuels 2Turning sunlight into liquid fuels 3A new view of oceanic phytoplankton 2A new view of oceanic phytoplankton 3Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |